VFVA - ETF AI Analysis
Top Page
Vanguard U.S. Value Factor ETF (VFVA)
VFVA’s rating suggests it is a solid, but not top-tier, value-focused ETF, supported by several strong holdings with good fundamentals and reasonable valuations. Standout positions like Verizon, Bristol-Myers Squibb, Salesforce, and Accenture contribute positively through strong financial performance, strategic growth initiatives, and generally favorable technical trends. However, holdings such as AT&T and General Motors, which face higher debt, competitive pressures, and financial or technical challenges, along with the fund’s tilt toward a few sectors like telecom and healthcare, add risk and help explain why the overall rating is moderated rather than excellent.
VFVA vs. SPDR S&P 500 ETF (SPY)
- AUM
- 968.19M
- Region
- North America
- Expense Ratio
- 0.13%
- Beta
- 0.85
- Issuer
- Vanguard
- Inception Date
- Feb 13, 2018
- Dividend Yield
- 1.77%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
VFVA Summary
Vanguard U.S. Value Factor ETF (VFVA) focuses on U.S. companies that appear undervalued based on their business fundamentals, following a “value” investing theme rather than a specific index. It spreads money across many sectors like financials, health care, energy, and technology, aiming for diversification while tilting toward cheaper stocks. Well-known holdings include Pfizer, Verizon, AT&T, and General Motors. Someone might invest in VFVA if they want broad U.S. stock exposure with an emphasis on value companies that could have long-term growth potential. A key risk is that value stocks can stay out of favor for long periods and the ETF can go up and down with the overall stock market.
How much will it cost me?
VFVA has an expense ratio of 0.13%, which means you’ll pay about $1.30 per year for every $1,000 invested. This cost is lower than the average ETF because it’s a passively managed, rules-based fund rather than a fully active stock-picking strategy.
What would affect this ETF?
VFVA focuses on U.S. value stocks across many sectors, so it could benefit if the U.S. economy stays healthy, interest rates stabilize or fall, and investors shift toward undervalued companies, especially in financials, health care, and energy where many of its holdings like Pfizer, EOG Resources, and Marathon Petroleum sit. On the downside, a U.S. slowdown, higher-for-longer interest rates, or renewed investor preference for fast-growing tech names over value stocks could weigh on performance, and company-specific issues at major holdings such as telecom or health insurers could also hurt returns.
VFVA Top 10 Holdings
VFVA leans heavily into U.S. value names, with health care and financials quietly steering the ship. Elevance Health and Cigna have been rising, giving the fund a solid defensive backbone, while Pfizer has stayed relatively steady as it works through post-pandemic growing pains. On the flip side, CRH has been lagging, acting as a bit of a speed bump, and Bristol-Myers Squibb has shown more mixed momentum. With all holdings U.S.-focused and no single mega-cap dominating, the ETF feels more like a broad value quilt than a high-octane growth rocket.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 EOG | EOG Resources | 0.85% | $8.28M | $77.14B | 37.74% | 78Outperform |
 GM | General Motors | 0.83% | $8.07M | $77.97B | 29.90% | 73Outperform |
 PFE | Pfizer | 0.81% | $7.86M | $175.50B | 21.41% | 74Outperform |
 BMY | Bristol-Myers Squibb | 0.79% | $7.75M | $131.21B | 35.85% | 78Outperform |
 CI | Cigna | 0.75% | $7.28M | $80.70B | 16.14% | 72Outperform |
 REGN | Regeneron | 0.73% | $7.14M | $96.26B | 40.16% | 78Outperform |
 CRH | CRH plc | 0.70% | $6.85M | $65.72B | -17.48% | 76Outperform |
 VZ | Verizon | 0.68% | $6.60M | $191.36B | 16.20% | 81Outperform |
 FDX | FedEx | 0.65% | $6.30M | $77.15B | 23.70% | 79Outperform |
 USB | US Bancorp | 0.64% | $6.21M | $95.10B | 27.83% | 76Outperform |
VFVA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For VFVA, the sentiment is Positive. The current price of 161.45 is above the 20-day moving average (MA) of 158.51, above the 50-day MA of 157.52, and above the 200-day MA of 147.40, indicating a bullish trend. The MACD of 1.97 indicates Negative momentum. The RSI at 69.76 is Neutral, neither overbought nor oversold. The STOCH value of 80.77 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VFVA.
VFVA Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| VFVA | $161.45 | $170.00(5.30% Upside) | $968.19M | 0.13% | 69Neutral |
 QVAL | $63.35 | $73.61(16.20% Upside) | $719.25M | 0.28% | 73Outperform |
 LSVD | $34.27 | $45.77(33.55% Upside) | $653.82M | 0.40% | 74Outperform |
 AIVL | $133.65 | $159.17(19.10% Upside) | $420.01M | 0.38% | 72Outperform |
 BUSA | $42.39 | $48.13(13.53% Upside) | $414.36M | 0.60% | 70Outperform |
 GVLU | $29.22 | $35.35(20.97% Upside) | $261.70M | 0.50% | 69Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VFVA | Vanguard U.S. Value Factor ETF | 161.45 | 38.28 | 31.08% | |
| QVAL | Alpha Architect U.S. Quantitative Value ETF | 63.35 | 17.62 | 38.53% | |
| LSVD | LSV Disciplined Value ETF | 34.27 | 5.73 | 20.07% | |
| AIVL | WisdomTree U.S. AI Enhanced Value Fund | 133.65 | 23.06 | 20.85% | |
| BUSA | Brandes U.S. Value ETF | 42.39 | 8.21 | 24.01% | |
| GVLU | Gotham 1000 Value ETF | 29.22 | 5.70 | 24.26% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.